Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients - PubMed (original) (raw)
doi: 10.1189/jlb.0803402. Epub 2003 Dec 4.
Affiliations
- PMID: 14657213
- DOI: 10.1189/jlb.0803402
Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients
Stephan Schmidt et al. J Leukoc Biol. 2004 Mar.
Abstract
Peroxisomal proliferator-activated receptors (PPARs) belong to a nuclear receptor superfamily of ligand-activated transcription factors. The PPAR-gamma isoform is expressed in human T lymphocytes, and oral administration of PPAR-gamma agonists ameliorates the clinical course and histopathological features in experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis, suggesting a potential role for PPAR-gamma agonists in the treatment of autoimmune diseases. To assess a potential therapeutic role of PPAR-gamma agonists in multiple sclerosis, we compared the immunomodulatory effects of the thiazolidinedione (TZD) drugs pioglitazone (PIO) and ciglitazone and the non-TZD PPAR-gamma agonist GW347845 on human T leukemia cells (Jurkat cells) and phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMCs) derived from 21 multiple sclerosis patients and 12 healthy donors. PIO, ciglitazone, and GW347845 suppressed PHA-induced T cell proliferation by 40-50% and secretion of interferon-gamma and tumor necrosis factor alpha, by 30-50%. Inhibition of proliferation was increased to approximately 80% and that of proinflammatory cytokine secretion, to 80-90% when PBMCs were first preincubated with PPAR-gamma agonists and re-exposed at the time of PHA stimulation, indicating a sensitizing effect of PPAR-gamma agonists. Inhibition of proliferation was also observed in the tetanus toxoid-specific T cell line KHS.TT2, albeit to a lesser extent. The antiproliferative effects of PIO and GW347845 were accompanied by a decrease of cell viability. Electron microscopy and Western blot analysis revealed DNA condensation and down-regulation of bcl-2, suggesting the induction of apoptosis in activated T lymphocytes. In summary, the data support the potential use of PPAR-gamma agonists as immunomodulatory, therapeutic agents for autoimmune diseases.
Similar articles
- Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. Feinstein DL, et al. Ann Neurol. 2002 Jun;51(6):694-702. doi: 10.1002/ana.10206. Ann Neurol. 2002. PMID: 12112074 - The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis.
Harris SG, Phipps RP. Harris SG, et al. Eur J Immunol. 2001 Apr;31(4):1098-105. doi: 10.1002/1521-4141(200104)31:4<1098::aid-immu1098>3.0.co;2-i. Eur J Immunol. 2001. PMID: 11298334 - Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.
Grommes C, Landreth GE, Heneka MT. Grommes C, et al. Lancet Oncol. 2004 Jul;5(7):419-29. doi: 10.1016/S1470-2045(04)01509-8. Lancet Oncol. 2004. PMID: 15231248 Review. - Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation.
Kielian T, Drew PD. Kielian T, et al. J Neurosci Res. 2003 Feb 1;71(3):315-25. doi: 10.1002/jnr.10501. J Neurosci Res. 2003. PMID: 12526021 Review.
Cited by
- Association between insulin resistance and multiple sclerosis: a systematic review and meta-analysis.
Sepidarkish M, Kalantari N, Gorgani-Firouzjaee T, Rostami-Mansoor S, Shirafkan H. Sepidarkish M, et al. Metab Brain Dis. 2024 Jun;39(5):1015-1026. doi: 10.1007/s11011-024-01347-2. Epub 2024 May 20. Metab Brain Dis. 2024. PMID: 38767742 Review. - Therapeutic modulation of JAK-STAT, mTOR, and PPAR-γ signaling in neurological dysfunctions.
Kumar S, Mehan S, Narula AS. Kumar S, et al. J Mol Med (Berl). 2023 Feb;101(1-2):9-49. doi: 10.1007/s00109-022-02272-6. Epub 2022 Dec 7. J Mol Med (Berl). 2023. PMID: 36478124 Review. - PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer.
Ballav S, Biswas B, Sahu VK, Ranjan A, Basu S. Ballav S, et al. Cells. 2022 Oct 13;11(20):3215. doi: 10.3390/cells11203215. Cells. 2022. PMID: 36291082 Free PMC article. Review. - Physiological Convergence and Antagonism Between GR and PPARγ in Inflammation and Metabolism.
Dacic M, Shibu G, Rogatsky I. Dacic M, et al. Adv Exp Med Biol. 2022;1390:123-141. doi: 10.1007/978-3-031-11836-4_7. Adv Exp Med Biol. 2022. PMID: 36107316 Review. - Role of JAK-STAT and PPAR-Gamma Signalling Modulators in the Prevention of Autism and Neurological Dysfunctions.
Khera R, Mehan S, Kumar S, Sethi P, Bhalla S, Prajapati A. Khera R, et al. Mol Neurobiol. 2022 Jun;59(6):3888-3912. doi: 10.1007/s12035-022-02819-1. Epub 2022 Apr 18. Mol Neurobiol. 2022. PMID: 35437700 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical